Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

UCB and AstraZeneca Form Alliance for the Commercialization of Cimzia(R) in Brazil

By Pharmaceutical Processing | September 28, 2009

UCB and AstraZeneca announced today that they have entered into a partnership to register and commercialize UCB’s PEGylated anti-TNF alpha drug Cimzia (certolizumab pegol) in Brazil. The drug is to be registered for the treatment of rheumatoid arthritis and Crohn’s disease. Under the agreement, AstraZeneca will register Cimzia and upon approval will be the exclusive distributor of Cimzia in Brazil. In partnership with UCB, AstraZeneca will have the right to distribute future new line extensions related to Cimzia. UCB retains the right to co-promote Cimzia as well as future line extensions in Brazil. This partnership with AstraZeneca will help UCB commercialize its rich pipeline of products and foster the growth of UCB’s affiliate in Brazil. “This is an important strategic partnership for us, and supports our combined focus on meeting patient needs and developing innovative medicines,” said Mark McDade, COO of UCB. “This relationship will ensure that as many Brazilian patients as possible get access to our innovative medicine Cimzia.” “This partnership with UCB will leverage AstraZeneca’s expertise in regulatory affairs, sales and marketing to help bring the benefits of Cimzia to patients in Brazil,” said Rubens Pedrosa, president and representative director of AstraZeneca Brazil. “AstraZeneca has been one of the fastest growing pharma companies in the country and Cimzia will complement our current portfolio of innovative medicines and support our continued growth in this important market.”

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE